CN114096165B - 一种缓解视疲劳的可食用组合物 - Google Patents
一种缓解视疲劳的可食用组合物 Download PDFInfo
- Publication number
- CN114096165B CN114096165B CN202180004535.4A CN202180004535A CN114096165B CN 114096165 B CN114096165 B CN 114096165B CN 202180004535 A CN202180004535 A CN 202180004535A CN 114096165 B CN114096165 B CN 114096165B
- Authority
- CN
- China
- Prior art keywords
- edible composition
- fruit extract
- total
- food
- coffee fruit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 80
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 47
- 235000013399 edible fruits Nutrition 0.000 claims abstract description 48
- 239000000284 extract Substances 0.000 claims abstract description 45
- 239000000843 powder Substances 0.000 claims abstract description 33
- 230000000694 effects Effects 0.000 claims abstract description 13
- 208000010412 Glaucoma Diseases 0.000 claims abstract description 11
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 claims description 24
- 235000013305 food Nutrition 0.000 claims description 24
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 claims description 20
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 claims description 20
- 229940074393 chlorogenic acid Drugs 0.000 claims description 20
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 claims description 20
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 claims description 20
- 235000001368 chlorogenic acid Nutrition 0.000 claims description 20
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 claims description 20
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 20
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 13
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 10
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 claims description 10
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 10
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 10
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 10
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 claims description 10
- 229940106189 ceramide Drugs 0.000 claims description 10
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 claims description 10
- 239000008101 lactose Substances 0.000 claims description 10
- 235000019359 magnesium stearate Nutrition 0.000 claims description 10
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 claims description 10
- 150000008104 phosphatidylethanolamines Chemical class 0.000 claims description 10
- 150000003905 phosphatidylinositols Chemical class 0.000 claims description 10
- 239000000600 sorbitol Substances 0.000 claims description 10
- 235000008939 whole milk Nutrition 0.000 claims description 10
- 238000002360 preparation method Methods 0.000 claims description 9
- 229920002774 Maltodextrin Polymers 0.000 claims description 8
- 239000005913 Maltodextrin Substances 0.000 claims description 8
- 229940035034 maltodextrin Drugs 0.000 claims description 8
- -1 phospholipid compound Chemical class 0.000 claims description 6
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 abstract description 34
- 150000003904 phospholipids Chemical class 0.000 abstract description 25
- 235000003392 Curcuma domestica Nutrition 0.000 abstract description 20
- 235000003373 curcuma longa Nutrition 0.000 abstract description 20
- 235000013976 turmeric Nutrition 0.000 abstract description 20
- 239000002994 raw material Substances 0.000 abstract description 18
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 abstract description 17
- 229930003268 Vitamin C Natural products 0.000 abstract description 17
- 235000019154 vitamin C Nutrition 0.000 abstract description 17
- 239000011718 vitamin C Substances 0.000 abstract description 17
- 230000000007 visual effect Effects 0.000 abstract description 15
- TZCPCKNHXULUIY-RGULYWFUSA-N 1,2-distearoyl-sn-glycero-3-phosphoserine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@H](N)C(O)=O)OC(=O)CCCCCCCCCCCCCCCCC TZCPCKNHXULUIY-RGULYWFUSA-N 0.000 abstract description 14
- ZWZWYGMENQVNFU-UHFFFAOYSA-N Glycerophosphorylserin Natural products OC(=O)C(N)COP(O)(=O)OCC(O)CO ZWZWYGMENQVNFU-UHFFFAOYSA-N 0.000 abstract description 14
- 208000024891 symptom Diseases 0.000 abstract description 12
- 230000002688 persistence Effects 0.000 abstract description 8
- 230000001965 increasing effect Effects 0.000 abstract description 6
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 238000009472 formulation Methods 0.000 abstract description 3
- 230000004310 photopic vision Effects 0.000 abstract description 3
- 244000008991 Curcuma longa Species 0.000 abstract 1
- 244000163122 Curcuma domestica Species 0.000 description 19
- 230000000052 comparative effect Effects 0.000 description 18
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 16
- SBJKKFFYIZUCET-JLAZNSOCSA-N Dehydro-L-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(=O)C1=O SBJKKFFYIZUCET-JLAZNSOCSA-N 0.000 description 12
- MBMBGCFOFBJSGT-KUBAVDMBSA-N docosahexaenoic acid Natural products CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCC(O)=O MBMBGCFOFBJSGT-KUBAVDMBSA-N 0.000 description 10
- 235000012754 curcumin Nutrition 0.000 description 8
- 239000004148 curcumin Substances 0.000 description 8
- 229940109262 curcumin Drugs 0.000 description 8
- VFLDPWHFBUODDF-UHFFFAOYSA-N diferuloylmethane Natural products C1=C(O)C(OC)=CC(C=CC(=O)CC(=O)C=CC=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-UHFFFAOYSA-N 0.000 description 8
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 7
- 229940055416 blueberry extract Drugs 0.000 description 7
- 235000019216 blueberry extract Nutrition 0.000 description 7
- 229940087603 grape seed extract Drugs 0.000 description 7
- 235000002532 grape seed extract Nutrition 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000001717 vitis vinifera seed extract Substances 0.000 description 7
- 238000005303 weighing Methods 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 6
- 208000030533 eye disease Diseases 0.000 description 6
- 229940068196 placebo Drugs 0.000 description 6
- 239000000902 placebo Substances 0.000 description 6
- 235000010356 sorbitol Nutrition 0.000 description 6
- 238000001035 drying Methods 0.000 description 5
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 5
- 235000015097 nutrients Nutrition 0.000 description 5
- 150000003254 radicals Chemical class 0.000 description 5
- 210000001525 retina Anatomy 0.000 description 5
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 4
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 235000010208 anthocyanin Nutrition 0.000 description 3
- 239000004410 anthocyanin Substances 0.000 description 3
- 229930002877 anthocyanin Natural products 0.000 description 3
- 150000004636 anthocyanins Chemical class 0.000 description 3
- 210000004556 brain Anatomy 0.000 description 3
- 210000000695 crystalline len Anatomy 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 235000016357 Mirtillo rosso Nutrition 0.000 description 2
- 206010057430 Retinal injury Diseases 0.000 description 2
- 244000077923 Vaccinium vitis idaea Species 0.000 description 2
- 235000017606 Vaccinium vitis idaea Nutrition 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 2
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 1
- 206010068906 Computer vision syndrome Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 206010060891 General symptom Diseases 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 208000020358 Learning disease Diseases 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000029091 Refraction disease Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000004430 ametropia Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000032677 cell aging Effects 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 230000001886 ciliary effect Effects 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000008451 emotion Effects 0.000 description 1
- 230000008717 functional decline Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 201000003723 learning disability Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 230000004483 macular pigment optical density Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000006883 memory enhancing effect Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 210000004237 neck muscle Anatomy 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 208000014733 refractive error Diseases 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000002438 stress hormone Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/10—Natural spices, flavouring agents or condiments; Extracts thereof
- A23L27/14—Dried spices
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L29/00—Foods or foodstuffs containing additives; Preparation or treatment thereof
- A23L29/015—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/20—Agglomerating; Granulating; Tabletting
- A23P10/28—Tabletting; Making food bars by compression of a dry powdered mixture
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23P—SHAPING OR WORKING OF FOODSTUFFS, NOT FULLY COVERED BY A SINGLE OTHER SUBCLASS
- A23P10/00—Shaping or working of foodstuffs characterised by the products
- A23P10/30—Encapsulation of particles, e.g. foodstuff additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/02—Acid
- A23V2250/028—Chlorogenic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/184—Emulsifier
- A23V2250/1852—Phosphatidyl Serine
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/18—Lipids
- A23V2250/186—Fatty acids
- A23V2250/1868—Docosahexaenoic acid
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2108—Caffeine, coffee extract
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2112—Curcumin, turmeric
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/20—Natural extracts
- A23V2250/21—Plant extracts
- A23V2250/2116—Flavonoids, isoflavones
- A23V2250/21166—Proanthocyanidins, grape seed extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/50—Polysaccharides, gums
- A23V2250/51—Polysaccharide
- A23V2250/5114—Dextrins, maltodextrins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/612—Lactose
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/60—Sugars, e.g. mono-, di-, tri-, tetra-saccharides
- A23V2250/64—Sugar alcohols
- A23V2250/642—Sorbitol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/70—Vitamins
- A23V2250/708—Vitamin C
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Botany (AREA)
- Ophthalmology & Optometry (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medical Informatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
一种缓解视疲劳的可食用组合物,以重量份计包括1‑10份的姜黄粉、1‑12份的全咖啡果实提取物、1‑20份的磷脂复合物、1‑15份的DHA、0.5‑5份的磷脂酰丝氨酸和0.1‑5份的维生素C。所述可食用组合物具有缓解视疲劳的作用,受试者试食1周后,明视持久度提高且与试食前有显著性差异;试食2周后,视疲劳症状总积分降低且与试食前有显著性差异;受试者试食8周后,其视野范围明显增大,显示此配方可预防青光眼的发生。所述全咖啡果实提取物与另外5种原料的组合具有较佳的协同功效。
Description
交叉参考相关引用
本申请要求2020年04月10日递交的申请号为202010277606.5、发明名称为“一种缓解视疲劳的可食用组合物”的中国专利申请的优先权,其全部内容通过引用结合在本申请中。
技术领域
本发明属于食品技术领域,涉及一种缓解视疲劳的可食用组合物。
背景技术
视疲劳是一种常见的眼部疾病,具体表现症状为眼部干涩、酸胀,视觉重影,以及间歇性视觉模糊,严重时会产生恶心、呕吐、眩晕、头痛、颈部肌肉紧张、肩部酸痛等全身症状,降低成年人的工作效率,导致青少年及儿童学习障碍,直接影响人们的工作与生活。轻度的视疲劳往往得不到人们的重视,导致视疲劳症状加重,长期反复出现视疲劳可能会引发多种眼部疾病,如干眼症、屈光不正、VDT(visual display terminal)综合症、电脑视觉综合症,加剧了年龄相关性眼病的发生。
现代营养学和医学研究表明导致视疲劳产生的原因主要包括以下几种学说:
(1)自由基学说:眼球长时间处于搜索注视状态,眼外肌和睫状肌代谢增加,造成代谢废物(包括氧自由基)产生积累增加,从而造成肌细胞结构损伤和功能下降,已有研究表明自由基可导致和加剧多种视网膜疾病。
(2)视细胞营养物质损耗学说:视细胞消耗过度,而所需营养物质供应不及时,造成黄斑及视网膜恢复时间延长。视细胞中营养物质主要包括叶黄素、VA、多不饱和脂肪酸、VB1、VB2、微量矿物质元素等。
(3)视网膜损伤学说:可见光在视网膜上的聚焦,产生高氧压、高聚光,易发生脂质过氧化反应而其产物吞噬视网膜色素上皮细胞导致其视网膜受损。
(4)视网膜细胞衰老学说:视网膜色素上皮细胞衰老,导致眼睛老化,进而引发与年龄相关性眼病,如黄斑色素光学密度(macular pigment optical density,MPOD)降低等。
发明内容
基于现有技术中存在的问题,本发明的目的在于提供一种缓解视疲劳的可食用组合物及其应用,该组合物能够有效缓解视疲劳,预防青光眼的发生。
本发明的目的通过以下技术手段得以实现:
一方面,本发明提供一种可食用组合物,该组合物以重量份计包括:
本发明的可食用组合物中,所述磷脂复合物不含有磷脂酰丝氨酸。
现有技术中未见全咖啡果实提取物在视疲劳和视神经保护方面的报道,发明人在长期试验中创造性的发现,将全咖啡果实提取物与姜黄粉、磷脂复合物、DHA、磷脂酰丝氨酸和维生素C混合后食用具有缓解视疲劳的作用。具体来说将这6种原料按照配比获得的组合物用于食用,研究发现受试者试食1周后明视持久度提高且与试食前有显著性差异,试食2周后视疲劳症状总积分降低且与试食前有显著性差异;同时研究发现仅食用此组合物中的单一原料全咖啡果实提取物或仅使用除了全咖啡果实提取物外的另外5种原料的组合物时,受试者明视持久度和视疲劳症状总积分皆无显著性变化,而将此6种原料搭配的组合物具有缓解视疲劳的协同功效;同时发现受试者食用8周后,其视野范围明显增大,显示此配方可预防青光眼的发生。
本发明中所用姜黄粉、全咖啡果实提取物、磷脂复合物、DHA、磷脂酰丝氨酸和维生素C等原料均可商购获得,也可按照现有技术自行制备得到。各原料应符合相关行业标准质量要求。
在一些具体实施例中,本发明可食用组合物中,所述姜黄粉主要功效成分姜黄素的含量在20%以上,例如:30%以上,40%以上,50%以上,60%以上,70%以上,80%以上,甚至90%以上。可根据姜黄粉中姜黄素含量的高低适当调整姜黄粉在本发明可食用组合物中的用量。
在一些具体实施例中,本发明可食用组合物中,所述全咖啡果实提取物是从咖啡全果提取的混合物,例如:全咖啡果实提取物可由咖啡果实经过乙醇水溶液提取,浓缩、干燥后制得。以全咖啡果实提取物质量为100%计,所述全咖啡果实提取物中的功效成分包括20%~50%的总绿原酸和0.5%~5%的原花青素;其中,所述总绿原酸中包括新绿原酸,所述新绿原酸在所述全咖啡果实提取物中的占比为1%~20%。
在一些具体实施例中,本发明可食用组合物中,所述磷脂复合物中的主要功效成分包括磷脂酰乙醇胺、磷脂酰胆碱、磷脂酰肌醇和神经酰胺,以磷脂复合物质量为100%计,其中,磷脂酰乙醇胺的含量为5%~5.5%,磷脂酰胆碱的含量为4%~5.5%,磷脂酰肌醇的含量为0.5%~1.8%,神经酰胺的含量为1.5%~2.5%,磷脂复合物中剩余还包括大部分蛋白质等成分。本发明中所采用的磷脂复合物可购自Lecico GmbH公司,也可以按照现有技术自行制备获得。
上述的可食用组合物中,优选地,该组合物由姜黄粉、全咖啡果实提取物、磷脂复合物、DHA、磷脂酰丝氨酸和维生素C组成。
本发明可食用组合物中,根据自由基学说和视网膜损耗学说,添加姜黄粉能够抑制金属离子介导的脂质过氧化,保护细胞内部DNA免受氧化脂质损伤;维生素C是晶状体的重要营养成分,其在晶状体中的含量远高于其他组织,维生素C摄入不足会导致晶状体浑浊,严重时会引发白内障,同时维生素C具有强抗氧化性,能够清除自由基、降低过氧化脂质水平,本发明中添加维生素C能够有效缓解年龄相关性眼病和视觉损伤;全咖啡果实提取物主要含有总绿原酸、新绿原酸和原花青素,能够降低脂质过氧化物对视网膜的损伤。根据视细胞营养物质损耗学说,本发明可食用组合物配方中补充添加DHA、磷脂复合物和磷脂酰丝氨酸。DHA是视网膜含量最丰富的多不饱和脂肪酸之一,能够提供视细胞生长所需的营养物质。通过添加磷脂复合物能够改善认知提高记忆力,磷脂复合物中的磷脂酰胆碱能够通过体内水解产生胆碱,是神经递质乙酰胆碱合成的前体物质;乙酰胆碱是脑部神经细胞之间,互相传递信息,建立起稳定联系,形成思考、思维能力的基础物质;充足的磷脂酰胆碱的摄入有利于形成更多的神经递质乙酰胆碱,使大脑更有活力,记忆力因此而增强,从而有助于智力的提高。磷脂酰丝氨酸能够降低体内过多应激激素水平,减轻压力,缓解脑部疲劳,促进注意力集中、提高警觉性和记忆力,缓解不良情绪。根据本发明具体实施例中的研究表明,本发明6种原料搭配的组合物具有协同增效作用,有助于缓解视疲劳,预防青光眼的发生。
此外,本发明中的全咖啡果实提取物与其他5种原料搭配后效果要优于越橘提取物、蓝莓提取物、葡萄籽提取物等含有原花青素的提取物与其他5种原料搭配后效果。
根据本发明的具体实施方案,优选地,该组合物以重量份计包括:
再一方面,本发明还提供上述可食用组合物在缓解视疲劳中的应用。具体地,提供了所述可食用组合物在制备具有缓解视疲劳功效的食物中的应用。
再一方面,本发明还提供上述可食用组合物在预防青光眼中的应用。具体地,提供了所述可食用组合物在制备具有预防青光眼功效的食物中的应用。
根据本发明的具体实施方案,上述应用中,所述食物包括有效量的上述可食用组合物,还可选择性包括辅料。
所述辅料可以是食品领域常用辅料,例如:山梨糖醇、麦芽糊精、硬脂酸镁、乳糖、全脂奶粉中的一种或多种的组合,但不限于此。
根据本发明的具体实施方案,上述应用中,所述食物以片剂、胶囊剂、粉剂或颗粒剂形式存在,但不限于此。所述片剂、胶囊剂、粉剂或颗粒剂的制备可以参照现有技术进行。
再一方面,本发明还提供一种食物,以该食物的总质量为100%计,包括:
上述的食物中,除了包括6种营养成分外,还包括食品领域常用辅料,例如:山梨糖醇、麦芽糊精、硬脂酸镁、乳糖、全脂奶粉中的一种或多种的组合,但不限于此。
根据本发明的具体实施方案,优选地,以该食物的总质量为100%计,包括:
再一方面,本发明还提供上述食物在缓解视疲劳中的应用。
再一方面,本发明还提供上述食物在预防青光眼中的应用。
本发明提供的可食用组合物具有缓解视疲劳的作用,受试者试食1周后,明视持久度提高且与试食前有显著性差异;试食2周后,视疲劳症状总积分降低且与试食前有显著性差异;受试者试食8周后,其视野范围明显增大,显示此配方可预防青光眼的发生。本发明的全咖啡果实提取物与另外5种原料的组合具有较佳的协同功效。
附图说明
图1为本发明实施例1不同组别组合物食用前后受试者视野范围变化对比图。
具体实施方式
为了对本发明的技术特征、目的和有益效果有更加清楚的理解,现对本发明的技术方案进行以下详细说明,但不能理解为对本发明的可实施范围的限定。以下实施例中各原料若无特殊说明,均为常规市售获得。
实施例1:
本实施例提供一种缓解视疲劳的可食用组合物,该组合物以重量份计包括:
其中,姜黄粉中姜黄素含量约为20%~30%,全咖啡果实提取物中总绿原酸含量约为30%~40%,新绿原酸含量约为10%~20%,原花青素含量约为1%~5%。磷脂复合物中磷脂酰乙醇胺的含量约为5%~5.5%,磷脂酰胆碱的含量约为4%~5.5%,磷脂酰肌醇的含量约为0.5%~1.8%,神经酰胺的含量约为1.5%~2.5%。
该组合物制备方法为:按照重量比例称取姜黄粉、全咖啡果实提取物(由咖啡果实经过乙醇水溶液提取,浓缩、干燥后制得)、磷脂复合物(购自Lecico GmbH公司)、DHA、磷脂酰丝氨酸、维生素C、山梨糖醇、硬脂酸镁、乳糖和全脂奶粉混合均匀,压片,制备得到缓解视疲劳的可食用组合物。
将本实施例制备的组合物给予受试者试食(4.8g/天食用量),对照组采用安慰剂组(除其他相同辅料及含量外,6种功效成分及含量以麦芽糊精补齐),考察不同组别试食期间明视持久度的变化(表1)和视疲劳症状总积分变化(表2),结果如下所示:
表1:
注:A与试食前比较P<0.01;a与试食前比较P<0.05;B与安慰剂组比较P<0.01,b与安慰剂组比较P<0.05,下表同理。
表2:
由表1、表2可知:试食前受试者明视持久度及视疲劳症状总积分情况差异均无统计学意义(P>0.05),具有组间可比性。试食8周后,安慰剂组试食前后的明视持久度和视疲劳症状总积分相比,无统计学意义(P>0.05);本实施例1组合物组的明视持久度呈现增加趋势,试食1周后与试食前及安慰剂组相比皆有显著性差异(P<0.05),且实施例1组合物组的明视持久度提高率大于10%;同时,实施例1组合物组的视疲劳症状总积分降低,与试食前有明显差异(P<0.05),因此,实施例1组合物组有助于缓解视疲劳。
此外,青光眼的初期症状表现为视野范围缩小,由图1可知食用实施例1组合物组8周后,受试者的视野范围明显增大,显示此配方可预防青光眼的发生。
实施例2:
本实施例提供一种缓解视疲劳的可食用组合物,该组合物以重量份计包括:
其中,姜黄粉中姜黄素含量约为20%~30%,全咖啡果实提取物中总绿原酸含量为约30%~40%,新绿原酸含量约为10%~20%,原花青素含量约为1%~5%。磷脂复合物中磷脂酰乙醇胺的含量约为5%~5.5%,磷脂酰胆碱的含量约为4%~5.5%,磷脂酰肌醇的含量约为0.5%~1.8%,神经酰胺的含量约为1.5%~2.5%。
该组合物制备方法为:按照重量比例称取姜黄粉、全咖啡果实提取物(由咖啡果实经过乙醇水溶液提取,浓缩、干燥后制得)、磷脂复合物(购自Lecico GmbH公司)、DHA、磷脂酰丝氨酸、维生素C、山梨糖醇、硬脂酸镁、乳糖和全脂奶粉混合均匀,压片,制备得到缓解视疲劳的可食用组合物。
实施例3:
本实施例提供一种缓解视疲劳的可食用组合物,该组合物以重量份计包括:
其中,姜黄粉中姜黄素含量约为20%~30%,全咖啡果实提取物中总绿原酸含量约为30%~40%,新绿原酸含量约为10%~20%,原花青素含量约为1%~5%。磷脂复合物中磷脂酰乙醇胺的含量约为5%~5.5%,磷脂酰胆碱的含量约为4%~5.5%,磷脂酰肌醇的含量约为0.5%~1.8%,神经酰胺的含量约为1.5%~2.5%。
该组合物制备方法为:按照重量比例称取姜黄粉、全咖啡果实提取物(由咖啡果实经过乙醇水溶液提取,浓缩、干燥后制得)、磷脂复合物(购自Lecico GmbH公司)、DHA、磷脂酰丝氨酸、维生素C、山梨糖醇、硬脂酸镁、乳糖和全脂奶粉混合均匀,压片,制备得到缓解视疲劳的可食用组合物。
对比例1:
本对比例提供一种缓解视疲劳的可食用组合物,该组合物以重量份计包括:
其中,全咖啡果实提取物中总绿原酸含量约为30%~40%,新绿原酸含量约为10%~20%,原花青素含量约为1%~5%。
该组合物制备方法为:按照重量比例称取全咖啡果实提取物(由咖啡果实经过乙醇水溶液提取,浓缩、干燥后制得)、山梨糖醇、硬脂酸镁、乳糖、全脂奶粉和麦芽糊精混合均匀,压片,制备得到缓解视疲劳的可食用组合物。
对比例2:
本对比例提供一种缓解视疲劳的可食用组合物,该组合物以重量份计包括:
其中,姜黄粉中姜黄素含量约为20%~30%。磷脂复合物中磷脂酰乙醇胺的含量约为5%~5.5%,磷脂酰胆碱的含量约为4%~5.5%,磷脂酰肌醇的含量约为0.5%~1.8%,神经酰胺的含量约为1.5%~2.5%。
该组合物制备方法为:按照重量比例称取姜黄粉、磷脂复合物(购自Lecico GmbH公司)、DHA、磷脂酰丝氨酸、维生素C、山梨糖醇、硬脂酸镁、乳糖、全脂奶粉和麦芽糊精混合均匀,压片,制备得到缓解视疲劳的可食用组合物。
对比例1相比本发明实施例1,只添加了一种功效成分全咖啡果实提取物,且功效成分用量相同。对比例2相比本发明实施例1,未添加功效成分全咖啡果实提取物,而是添加了另外5种功效成分姜黄粉、磷脂复合物、DHA、磷脂酰丝氨酸、维生素C。按照实施例1的实验方法,实验结果如下述表3和表4所示。
表3:
表4:
由表3和表4可知,试食9周后,对比例1组合物组及对比例2组合物组在明视持久度及视疲劳症状总积分皆无明显变化,与安慰剂组相比也无显著性差异。
由此可知,只有将此组合物中所有功效原料配比后食用,才具有缓解视疲劳作用,使用其中的部分原料难以达到缓解视疲劳的效果。
对比例3:
本对比例提供一种可食用组合物,其与实施例1的区别在于将全咖啡果实提取物替换为市售的葡萄籽提取物,该组合物以重量份计包括:
其中,姜黄粉中姜黄素含量约为20%~30%,葡萄籽提取物原花青素含量不低于90%。磷脂复合物中磷脂酰乙醇胺的含量约为5%~5.5%,磷脂酰胆碱的含量约为4%~5.5%,磷脂酰肌醇的含量约为0.5%~1.8%,神经酰胺的含量约为1.5%~2.5%。
该组合物制备方法为:按照重量比例称取姜黄粉、葡萄籽提取物、磷脂复合物(购自Lecico GmbH公司)、DHA、磷脂酰丝氨酸、维生素C、山梨糖醇、硬脂酸镁、乳糖、全脂奶粉和麦芽糊精混合均匀,压片,制备得到缓解视疲劳的可食用组合物。
对比例4:
本对比例提供一种可食用组合物,其与实施例1的区别在于将全咖啡果实提取物替换为市售的蓝莓提取物,该组合物以重量份计包括:
其中,姜黄粉中姜黄素含量约为20%~30%,蓝莓提取物花青素含量不低于20%。磷脂复合物中磷脂酰乙醇胺的含量约为5%~5.5%,磷脂酰胆碱的含量约为4%~5.5%,磷脂酰肌醇的含量约为0.5%~1.8%,神经酰胺的含量约为1.5%~2.5%。
该组合物制备方法为:按照重量比例称取姜黄粉、蓝莓提取物、磷脂复合物(购自Lecico GmbH公司)、DHA、磷脂酰丝氨酸、维生素C、山梨糖醇、硬脂酸镁、乳糖、全脂奶粉和麦芽糊精混合均匀,压片,制备得到缓解视疲劳的可食用组合物。
对比例3和对比例4相比本发明实施例1,只将全咖啡果实提取物分别替换为葡萄籽提取物和蓝莓提取物,各提取物用量相同,葡萄籽提取物中功效成分原花青素(含量≥90%)要远高于本发明的全咖啡果实提取物中的功效成分原花青素(含量1%~5%),且不含有全咖啡果实提取物的功效成分总绿原酸及新绿原酸;蓝莓提取物中的功效成分为花青素(含量≥20%),其不同于本发明全咖啡果实提取物的功效成分。按照实施例1的实验方法,将对比例3和对比例4制备的组合物给予受试者试食(4.8g/天食用量),考察不同组别试食期间明视持久度的变化,实验结果如下述表5所示。
表5:
由表5可知,试食4周后,对比例3组合物组及对比例4组合物组在明视持久度无明显变化,结合表1对比看出,受试者食用1周的实施例1组合物明视持久度即有明显提升。
综上可知,只有将本发明组合物中所有功效原料配比后食用,才具有缓解视疲劳作用,使用其中的部分原料难以达到缓解视疲劳的效果。同时,本发明的全咖啡果实提取物与其他5种原料搭配后效果要优于越橘提取物、蓝莓提取物、葡萄籽提取物等含有原花青素、花青素的提取物与其他5种原料搭配后效果。
Claims (11)
1.一种可食用组合物,该组合物以重量份计包括:
其中,以全咖啡果实提取物质量为100%计,所述全咖啡果实提取物中的功效成分包括20%~50%的总绿原酸和0.5%~5%的原花青素;其中,所述总绿原酸中包括新绿原酸,所述新绿原酸在所述全咖啡果实提取物中的占比为1%~20%;
以磷脂复合物质量为100%计,所述磷脂复合物中的功效成分包括5%~5.5%的磷脂酰乙醇胺、4%~5.5%的磷脂酰胆碱、0.5%~1.8%的磷脂酰肌醇和1.5%~2.5%的神经酰胺。
2.根据权利要求1所述的可食用组合物,该组合物以重量份计由以下组分组成:
3.根据权利要求1所述的可食用组合物,该组合物以重量份计包括:
4.权利要求1~3任一项所述可食用组合物在制备具有缓解视疲劳功效的食物中的应用。
5.权利要求1~3任一项所述可食用组合物在制备具有预防青光眼功效的食物中的应用。
6.根据权利要求4或5所述的应用,其中,所述食物包括有效量的权利要求1~3任一项所述可食用组合物。
7.根据权利要求6所述的应用,其中,所述食物还包括辅料。
8.根据权利要求7所述的应用,其中,所述辅料包括山梨糖醇、麦芽糊精、硬脂酸镁、乳糖、全脂奶粉中的一种或多种的组合。
9.根据权利要求7所述的应用,其中,所述食物以片剂、胶囊剂、粉剂或颗粒剂形式存在。
10.一种食物,以该食物的总质量为100%计,包括:
其中,以全咖啡果实提取物质量为100%计,所述全咖啡果实提取物中的功效成分包括20%~50%的总绿原酸和0.5%~5%的原花青素;其中,所述总绿原酸中包括新绿原酸,所述新绿原酸在所述全咖啡果实提取物中的占比为1%~20%;
以磷脂复合物质量为100%计,所述磷脂复合物中的功效成分包括5%~5.5%的磷脂酰乙醇胺、4%~5.5%的磷脂酰胆碱、0.5%~1.8%的磷脂酰肌醇和1.5%~2.5%的神经酰胺。
11.根据权利要求10所述的食物,其中,以该食物的总质量为100%计,包括:
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010277606 | 2020-04-10 | ||
CN2020102776065 | 2020-04-10 | ||
PCT/CN2021/079008 WO2021203878A1 (zh) | 2020-04-10 | 2021-03-04 | 一种缓解视疲劳的可食用组合物 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN114096165A CN114096165A (zh) | 2022-02-25 |
CN114096165B true CN114096165B (zh) | 2023-09-19 |
Family
ID=78022680
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202180004535.4A Active CN114096165B (zh) | 2020-04-10 | 2021-03-04 | 一种缓解视疲劳的可食用组合物 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20230048358A1 (zh) |
EP (1) | EP4133950A4 (zh) |
JP (1) | JP7471690B2 (zh) |
KR (1) | KR20220164040A (zh) |
CN (1) | CN114096165B (zh) |
TW (1) | TWI773205B (zh) |
WO (1) | WO2021203878A1 (zh) |
Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1839815A (zh) * | 2006-01-20 | 2006-10-04 | 深圳市生物谷科技有限公司 | 一种含有咖啡酰奎宁酸的药物组合物 |
CN104397687A (zh) * | 2014-11-10 | 2015-03-11 | 厦门金达威集团股份有限公司 | 含多不饱和脂肪酸的营养组合物及其制备方法与应用 |
WO2017135466A1 (ja) * | 2016-02-05 | 2017-08-10 | 参天製薬株式会社 | キサントフィルとヒシ属植物の加工物を含有する組成物 |
CN107375504A (zh) * | 2017-08-15 | 2017-11-24 | 庞会心 | 一种预防和治疗视疲劳的组合物及其制备方法与应用 |
CN108095112A (zh) * | 2017-12-18 | 2018-06-01 | 苏州诺衡生命科技有限公司 | 一种有助于缓解视疲劳保健食品及制备方法 |
CN108294305A (zh) * | 2017-12-15 | 2018-07-20 | 成都图径生物科技有限公司 | 含原花青素的缓解视疲劳组合物 |
CN108347957A (zh) * | 2015-09-04 | 2018-07-31 | 寇菲福瑞特私人有限公司 | 咖啡果实提取物和粉末的制备 |
CN108338980A (zh) * | 2017-01-23 | 2018-07-31 | 四川九章生物科技有限公司 | 绿原酸在制备防治眼部炎症的药物中的用途 |
CN108542883A (zh) * | 2018-04-26 | 2018-09-18 | 北京蓝丹医药科技有限公司 | 一种眼外施用的喷雾剂 |
CN109222086A (zh) * | 2018-09-12 | 2019-01-18 | 无限极(中国)有限公司 | 一种具有缓解视疲劳功效的组合物及其应用和保健食品 |
CN109527313A (zh) * | 2018-12-18 | 2019-03-29 | 西藏民族大学 | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI365716B (en) * | 2003-12-02 | 2012-06-11 | Suntory Holdings Ltd | Oil or fat and oil compositions containing phospholipids and a long-chain polyunsaturated fatty acid supply compound, and food using same |
JP2007297304A (ja) | 2006-04-28 | 2007-11-15 | Kao Corp | 大脳疲労回復剤 |
KR100926387B1 (ko) | 2007-10-01 | 2009-11-11 | (주) 서울바이오메드 | 클로로겐산 및 그 유도체를 포함하는 결막염 치료용 조성물 |
US20180042978A1 (en) | 2008-04-10 | 2018-02-15 | U.S. Nutraceuticals, Llc D/B/A Valensa International | Method of treating photo-induced ocular fatigue and associated reduction in speed of ocular focus |
US8652518B2 (en) | 2012-04-15 | 2014-02-18 | Jahahreeh Finley | Compositions and methods for the prevention and treatment of diseases or conditions associated with oxidative stress, inflammation, and metabolic dysregulation |
EP3218006A4 (en) | 2014-11-11 | 2018-08-15 | Verdure Sciences | Stable solid lipid particle composition for improved bioavailability of lipophilic compounds for age-related diseases |
CN106889412A (zh) * | 2017-01-17 | 2017-06-27 | 安徽元麦凡康食品有限公司 | 一种提神抗疲劳固体饮料 |
US20190159474A1 (en) | 2017-11-29 | 2019-05-30 | Lytone Enterprise, Inc. | Ameliorative effects of a whole coffee fruit extract on age-related neurodegenerative disease |
CN109288056A (zh) * | 2018-10-08 | 2019-02-01 | 徐晓飞 | 一种含姜黄素、ω-3多不饱和脂肪酸和磷脂的组合物及其应用 |
CN110558468A (zh) | 2019-10-21 | 2019-12-13 | 邓凡 | 一种模块化不含常见致敏原的全营养饮料配方 |
-
2021
- 2021-03-04 WO PCT/CN2021/079008 patent/WO2021203878A1/zh unknown
- 2021-03-04 KR KR1020227038637A patent/KR20220164040A/ko active Search and Examination
- 2021-03-04 EP EP21785428.0A patent/EP4133950A4/en active Pending
- 2021-03-04 CN CN202180004535.4A patent/CN114096165B/zh active Active
- 2021-03-04 JP JP2022560892A patent/JP7471690B2/ja active Active
- 2021-03-19 TW TW110109934A patent/TWI773205B/zh active
-
2022
- 2022-10-10 US US17/962,753 patent/US20230048358A1/en active Pending
Patent Citations (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1839815A (zh) * | 2006-01-20 | 2006-10-04 | 深圳市生物谷科技有限公司 | 一种含有咖啡酰奎宁酸的药物组合物 |
CN104397687A (zh) * | 2014-11-10 | 2015-03-11 | 厦门金达威集团股份有限公司 | 含多不饱和脂肪酸的营养组合物及其制备方法与应用 |
CN108347957A (zh) * | 2015-09-04 | 2018-07-31 | 寇菲福瑞特私人有限公司 | 咖啡果实提取物和粉末的制备 |
WO2017135466A1 (ja) * | 2016-02-05 | 2017-08-10 | 参天製薬株式会社 | キサントフィルとヒシ属植物の加工物を含有する組成物 |
CN108338980A (zh) * | 2017-01-23 | 2018-07-31 | 四川九章生物科技有限公司 | 绿原酸在制备防治眼部炎症的药物中的用途 |
CN107375504A (zh) * | 2017-08-15 | 2017-11-24 | 庞会心 | 一种预防和治疗视疲劳的组合物及其制备方法与应用 |
CN108294305A (zh) * | 2017-12-15 | 2018-07-20 | 成都图径生物科技有限公司 | 含原花青素的缓解视疲劳组合物 |
CN108095112A (zh) * | 2017-12-18 | 2018-06-01 | 苏州诺衡生命科技有限公司 | 一种有助于缓解视疲劳保健食品及制备方法 |
CN108542883A (zh) * | 2018-04-26 | 2018-09-18 | 北京蓝丹医药科技有限公司 | 一种眼外施用的喷雾剂 |
CN109222086A (zh) * | 2018-09-12 | 2019-01-18 | 无限极(中国)有限公司 | 一种具有缓解视疲劳功效的组合物及其应用和保健食品 |
CN109527313A (zh) * | 2018-12-18 | 2019-03-29 | 西藏民族大学 | 一种可缓解视觉和体力疲劳的功能性饮料及其制备方法 |
Non-Patent Citations (3)
Title |
---|
咖啡护眼;祝你幸福(午后)(05);第60页 * |
科技新发现;消费指南(07);第11页 * |
缓解视疲劳功能食品及其功效成分研究进展;金鑫;臧茜茜;葛亚中;邓乾春;高擎;陈鹏;黄凤洪;;食品科学(03);第258-264页 * |
Also Published As
Publication number | Publication date |
---|---|
JP2023520578A (ja) | 2023-05-17 |
EP4133950A4 (en) | 2023-10-25 |
TWI773205B (zh) | 2022-08-01 |
TW202143992A (zh) | 2021-12-01 |
US20230048358A1 (en) | 2023-02-16 |
JP7471690B2 (ja) | 2024-04-22 |
CN114096165A (zh) | 2022-02-25 |
WO2021203878A1 (zh) | 2021-10-14 |
EP4133950A1 (en) | 2023-02-15 |
KR20220164040A (ko) | 2022-12-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2138055B1 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
US9889173B2 (en) | Composition for improving macular pigment density and preventing or treating age-related macular degeneration | |
US20050249821A1 (en) | Nutritional supplement for treatment of ocular diseases | |
DE69630195T2 (de) | Verwendung eines ausgleichenden zusatzstoffes für omega-6 und omega-3 ungesättigte fettsäure | |
AU780120B2 (en) | Compositions normalizing circadian rhythm | |
CN102210474B (zh) | 一种护眼健脑泡腾片剂 | |
EP1317264B1 (de) | Kombination von liponsäure und konjuensäuren zur behandlung diabetischer störungen | |
CN109315491A (zh) | 一种促进视力发育的婴幼儿配方奶粉及其制备方法 | |
CN108041609B (zh) | 一种具有缓解视疲劳、预防近视的食品组合物及其制备方法 | |
EP2736354B1 (de) | Verwendung von citrullin und ein kombinationspräparat zur verbesserung der männlichen fertilität | |
CN105520137B (zh) | 一种具有缓解视疲劳和保护视力功能的保健食品 | |
CN114096165B (zh) | 一种缓解视疲劳的可食用组合物 | |
US20080268039A1 (en) | Loquat compositions | |
WO2002094253A1 (fr) | Agents attenuant une erreur de fonction de controle de l'oeil | |
EP0502766B1 (fr) | Compositions diététiques à base de lipides phosphorylés et leur utilisation dans l'amélioration des troubles de la vision | |
CN117653691A (zh) | 一种tsyi-610的组合物及用于治疗眼睛疾病的医药品用途 | |
KR20230067746A (ko) | 루테인을 유효성분으로 함유하는 액상 조성물 및 사료 조성물 | |
CN114680336A (zh) | 一种含火麻仁不饱和脂肪酸的滴剂及其制备方法 | |
CN117442641A (zh) | 一种缓解眼部不适的组合物及其制备方法 | |
CN111991437A (zh) | 一种保护视力的软胶囊配方及其制备方法 | |
CN115887521A (zh) | 一种缓解视觉疲劳的组合物及其制备方法 | |
CN107828618A (zh) | 一种保健白酒 | |
CN111642658A (zh) | 抗皱补水组合物 | |
Maci | Increasing Lutein Consumption–Are all Luteins Alike? | |
CN112867486A (zh) | 表现出增强的氧化稳定性的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |